Abbott Reports Strong Earnings, Forecasts Growth Despite Exact Sciences Integration Impact

Abbott Laboratories reported better-than-expected financial results, primarily driven by its medical device segment. The company also provided a 2026 forecast, projecting 6.5%-7.5% comparable sales growth, though it anticipates a $0.20 EPS dilution due to the ongoing integration of Exact Sciences.